Improved Side-Effect Stimulation Thresholds and Postoperative Transient Confusion With Asleep, Image-Guided Deep Brain Stimulation

Rohit Kesarwani; Uma V Mahajan; Alexander S Wang; Camilla Kilbane; Aasef G Shaikh; Jonathan P Miller; Jennifer A Sweet

doi:10.1227/ons.0000000000001076

Improved Side-Effect Stimulation Thresholds and Postoperative Transient Confusion With Asleep, Image-Guided Deep Brain Stimulation

Oper Neurosurg (Hagerstown). 2024 Feb 2. doi: 10.1227/ons.0000000000001076. Online ahead of print.

Authors

Rohit Kesarwani^{1

2

3}, Uma V Mahajan¹, Alexander S Wang^{1

4}, Camilla Kilbane^{1

4}, Aasef G Shaikh^{1

4

5}, Jonathan P Miller^{1

2}, Jennifer A Sweet^{1

2}

Affiliations

¹ Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
² Department of Neurological Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
³ Current Affiliation: Meritas Health Neurosurgery, North Kansas City Hospital, North Kansas City, Missouri, USA.
⁴ Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
⁵ United States Department of Veterans Affairs, Washington, District of Columbia, USA.

PMID: 38305427
DOI: 10.1227/ons.0000000000001076

Abstract

Background and objectives: Asleep, image-guided deep brain stimulation (DBS) is a modern alternative to awake, microelectrode recording (MER) guidance. Studies demonstrate comparable efficacy and complications between techniques, although some report lower stimulation thresholds for side effects with image guidance. In addition, few studies directly compare the risk of postoperative transient confusion (pTC) across techniques. The purpose of this study was to compare clinical efficacy, stimulation thresholds for side effects, and rates of pTC with MER-guided DBS vs intraoperative 3D-fluoroscopy (i3D-F) guidance in Parkinson's disease and essential tremor.

Methods: Consecutive patients from 2006 to 2021 were identified from the departmental database and grouped as having either MER-guided DBS or i3D-F-guided DBS insertion. Directional leads were used once commercially available. Changes in Unified Parkinson's Disease Rating Scale (UPDRS)-III scores, levodopa equivalent daily dose, Fahn-Tolosa-Marin scores, and stimulation thresholds were assessed, as were rates of complications including pTC.

Results: MER guidance was used to implant 487 electrodes (18 globus pallidus interna, GPi; 171 subthalamic nucleus; 76 ventrointermediate thalamus, VIM) in 265 patients. i3D-F guidance was used in 167 electrodes (19 GPi; 25 subthalamic nucleus; 41 VIM) in 85 patients. There were no significant differences in Unified Parkinson's Disease Rating III Scale, levodopa equivalent daily dose, or Fahn-Tolosa-Marin between groups. Stimulation thresholds for side effects were higher with i3D-F guidance in the subthalamic nucleus (MER, 2.80 mA ± 0.98; i3D-F, 3.46 mA ± 0.92; P = .002) and VIM (MER, 2.81 mA ± 1.00; i3D-F, 3.19 mA ± 1.03; P = .0018). Less pTC with i3D-F guidance (MER, 7.5%; i3D-F, 1.2%; P = .034) was also found.

Conclusion: Although clinical efficacy between MER-guided and i3D-F-guided DBS was comparable, thresholds for stimulation side effects were higher with i3D-F guidance and the rate of pTC was lower. This suggests that image-guided DBS may affect long-term side effects and pose a decreased risk of pTC.

Copyright © 2024 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.